Detail akcie Theravance Bioph-WI online

Business Summary: Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Theravance Biopharma Inc revenues increased 45% to $41.6M. Net income totaled $41.3M vs. loss of $28.2M. Revenues reflect Viatris collaboration agreement increase of 19% to $34.1M. Net Income reflects share-based compensation decrease of 8% to $7.4M (expense), Stock-based Compensation in Research decrease of 21% to $2.1M (expense).